Results 121 to 130 of about 15,373 (177)

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial. [PDF]

Signal Transduct Target Ther
Wu W, Yang Y, Chen H, Lu Y, Zeng Y, Zhao J, Du C, Lin Y, Peng P, Huang M, Zhang Y, Ouyang Q, Ding L, Cheng Z, Wen Y, Wu Z, Ye J, Ling L, Wang K, Lu Y, Zou G, Zhong J, Wang H, Lin D, Zeng, Yao C, Chen Q, Zou L, Wang S, Yu Y, Yuan Z, Wang Y, Yao H.   +32 more
europepmc   +1 more source

From Concept to Clinic: Vepdegestrant (ARV 471) Becomes the First Approved PROTAC Drug. [PDF]

Pharmaceutics
Bege M, Lovas M, Borbás A.
europepmc   +1 more source

Targeting Estrogen Receptor for Breast Cancer. [PDF]

Curr Issues Mol Biol
Yiannakopoulou E.
europepmc   +1 more source

Oral Estrogen Receptor Degraders Compared to Standard Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Goldvaser H, Khutsurauli S, Buchinger M, Safonov A, Grinshpun A.   +4 more
europepmc   +1 more source

Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence. [PDF]

Oncol Ther
Martin M, Rosca A, Vitko AS, Coersmeyer M, Moreira K, Li H, Mayer EL.   +6 more
europepmc   +1 more source

Clinical Advances in Breast Cancer: A Comprehensive Overview of Full-Course Disease Management. [PDF]

Cancer Innov
Peng X, Tan Y, Ma F.
europepmc   +1 more source

ICAM2 promotes endocrine resistance via dynein-mediated OXPHOS activation in ER-positive breast cancer. [PDF]

Cell Death Dis
Chen S, Wu S, Hu J, Liu B, Liu Y, Yang S, Tang F, He Y, Liu Q, Liu Y, Du Y, Zhang G, Guo Q, Gao F, Yang C.   +14 more
europepmc   +1 more source

Oestrogen receptors regulate vascular β₁- and β₃-adrenoceptor expression and shape sex-specific adrenergic control of vascular tone. [PDF]

Pflugers Arch
Riedel K, Deussen A, Zatschler B, Hentsche C, Müller B, Speier S, Reeps C, Tugtekin SM, Matschke K, Kopaliani I.   +9 more
europepmc   +1 more source

Cardiovascular toxicity of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in HR+/HER2- breast cancer: a real-world study based on the FAERS database. [PDF]

Front Pharmacol
Ma S, Li L, Chen Y, Zhao Y.
europepmc   +1 more source

<i>CDK4/6</i> Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions. [PDF]

Cancers (Basel)
Guan M, Hao H.
europepmc   +1 more source